Loading

0%

Biotech
Pipeline Builder Companies

Suite of Pipeline Builder Companies to accelerate the development of the most promising academic projects in life sciences

andzonbio

The Need

Driven by the need for a new model in biotech innovation, AdBio Partners and Inserm Transfert have launched AndzonBio.

With a hands-on and expert-driven approach, AndzonBio will accelerate the industrial development of the most promising academic projects in life sciences.

Two Partners

Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm), is responsible for the value creation of innovations at Inserm and its academic partners in human health and promotes long-term technology transfers in line with international best practices. Inserm Transfert SA was founded in 2000. It manages, under a Public Service Concession Agreement (Concession de Service Public), the entire promotion and transfer of knowledge emerging from the Inserm research laboratories to the industrial world, from invention disclosure to industrial partnerships and start-ups incorporation. Inserm Transfert also offers services relating to setting up and managing national, European and international projects, as well as supporting the technology transfer of clinical research and health data/databases an cohorts.

In 2009, Inserm Transfert and Inserm established an investment fund to finance proofs of concept. In 2005, Inserm Transfert Initiative, a dedicated seed money fund for life sciences, was created. Since 2017 a pathway for pre-entrepreneurship supports researchers inventors who aspire to become involved in entrepreneurship. In 2022, Inserm Transfert decided to become LPs in AFB Fund II in order to increase the opportunity of investment of seed fund in Inserm Transfert spin-off.

AdBio partners is an AMF-regulated (the French financial market authority) company that invests in a range of sectors within life sciences - specifically in therapeutics. AdBio partners’ unique strategy combines early-stage investments in promising companies and strong entrepreneurial support to strengthen the company’s growth.

Created in 2016, AdBio partners has made 25 European investments in France, Belgium and, Spain with two funds. AdBio partners has developed strong relationships within the European innovation ecosystem; as a result, it has attracted more than 50 international VC firms to invest in its portfolio companies. The operational team is composed of investment professionals with extensive corporate experience, combined with strong scientific, medical and operational expertise.

AndzonBio
Pipeline Builder Model

The AndzonBio Model is built on the conviction that focusing on specific therapeutic areas, combined with a hands-on, expert-driven approach, is the key to unlocking the full potential of each academic project.

With a dedicated team of industry leaders, AndzonBio ensures that promising projects receive the necessary expertise, validation, and resources to accelerate their transition into viable biotech companies.

The key features of this studios model include:
• A defined therapeutic area per studio, ensuring deep expertise and focus
• A rigorous selection process for carefully chosen programs
• A substantial R&D budget per program to get them on track for regulatory and clinical development
• A focus on a limited range of therapeutic modalities

Our Pipeline Builder companies

Neuro inflammation

#1AndzonBio1

Cardio, Vascular, Renal & Metabolism

June 2024

Open studio

News

October 29, 2024

AndzonBio1 raises initial €3M in seed funding to advance breakthrough treatments for Cardiovascular, Renal and Metabolic Disorders

AndzonBio1 raises initial €3M in seed funding to advance breakthrough treatments for Cardiovascular, Renal and Metabolic Disorders

June 18, 2024

Inserm Transfert and AdBio partners launch AndzonBio®

Inserm Transfert and AdBio partners launch AndzonBio

Contact

Press and analyst contacts